Notably, for zone I ROP (an area with a radius of twice the distance between the optic nerve disc and the fovea), the efficacy of anti-VEGF treatments (bevacizumab at 91% and ranibizumab at 78%) surpassed that of laser therapy, which stood at 66% [13]. Here, VEGFA is linked to retinopathy of prematurity.